Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Genmab A/S (NASDAQ:GMAB) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $39.17.

Several research analysts recently issued reports on the company. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. HC Wainwright restated a “buy” rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $2,463,000. AIMZ Investment Advisors LLC acquired a new stake in Genmab A/S in the 4th quarter valued at approximately $3,525,000. Northern Trust Corp increased its holdings in Genmab A/S by 18.8% in the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company’s stock valued at $12,509,000 after purchasing an additional 94,858 shares during the last quarter. Sei Investments Co. raised its position in Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock valued at $1,205,000 after purchasing an additional 20,525 shares during the period. Finally, LPL Financial LLC lifted its stake in Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company’s stock worth $4,079,000 after purchasing an additional 6,288 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $23.09 on Friday. The stock has a 50 day moving average price of $20.46 and a 200-day moving average price of $20.73. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The stock has a market cap of $14.81 billion, a price-to-earnings ratio of 13.27, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.